Lack of association between rheumatoid factor levels and clinical response to certolizumab pegol in patients with rheumatoid arthritis: an observational study
Drugs in Context · 11.08.2026 · 1
DOI: 10.7573/dic.2026-1-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drugs in Context, online erschienen am 11.08.2026. Verfasst von Adriana Maria Kakehasi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: UCB.
Abstract (Originalsprache)
Background
Patients with rheumatoid arthritis (RA) generally have elevated levels of rheumatoid factor (RF), which binds to the crystallizable fraction (Fc) of monoclonal antibodies, diminishing tumour necrosis factor inhibitor (TNFi) efficacy. We assessed clinical response to PEGylated, Fc-free certolizumab pegol (CZP) across baseline RF levels in Brazilian patients with RA.
Methods
Reported patients (>6 months disease duration) received CZP (200 mg every 2 weeks [Q2W] or 400 mg Q4W) after failure or intolerance to conventional synthetic or biologic disease-modifying antirheumatic drugs. Data were collected from medical records before initiation, at 3 months and at 6 months of CZP. Patients were stratified by baseline RF quartiles. Disease activity was assessed by the Clinical Disease Activity Index (CDAI).
Results
Amongst 51 patients, 49 (96.1%) were women, the mean age (standard deviation [SD]) was 49.8 (13.7) years and 23 (45.1%) were receiving methotrexate. RA duration (SD) was 17.0 (9.5) years. Of 43 patients with baseline RF values, mean RF (SD) was 224.3 (363.5) IU/mL. At baseline, 3 months and 6 months, CDAI for patients overall was 18.6 (10.4), 9.8 (8.6) and 12.5 (11.7); for those with baseline RF≤Q3 (n=34) versus >Q3 (n=9), CDAI was 18.4 (11.0) versus 20.0 (10.7), 9.2 (7.9) versus 8.4 (9.8) and 12.8 (13.2) versus 10.9 (8.9). CDAI remission/ low disease activity rates at baseline, 3 months and 6 months were 4.1%/18.4%, 23.4%/29.8% and 11.9%/40.5%; for those with baseline RF≤Q3 (n=34) versus >Q3 (n=9), CDAI remission/low disease activity rates were 2.9%/20.6% versus 11.1%/0.0% at baseline, 30.3%/24.2% versus 12.5%/50.0% at 3 months and 14.3%/42.9% versus 12.5%/37.5% at 6 months.
Conclusion
Baseline RF values did not appear to influence CZP clinical response in this cohort of patients with RA. However, small sample size and data heterogeneity restricted generalizability. Efficacy data from larger cohorts may further elucidate the impact of high RF levels in patients receiving Fc-free biologics. Download the Plain Language Summary of this article: https://www.drugsincontext.com/plain-language-summaries/plain-language-summary-lack-of-association-between-rheumatoid-factor-levels-and-clinical-response-to-certolizumab-pegol-in-patients-with-rheumatoid-arthritis-an-observational-study
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
- Programa de Pós-graduação em Ciências Aplicadas à Saúde do Adulto, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
- Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
- Santa Casa de Belo Horizonte, Belo Horizonte, Brazil.
- Hospital Universitário, Universidade Federal de Juiz de Fora, Juiz de Fora, Brazil.
- UCB, São Paulo, Brazil.
Förderung
- UCB
Zitieren
APA
Kakehasi, A. M., Sperancini Amaral, J. G. L., Martins Amaral, J., Ubirajara E Silva de Souza, M. P. G., de Souza, V. A., Damian, G. B., & Torigoe, D. Y. (2026). Lack of association between rheumatoid factor levels and clinical response to certolizumab pegol in patients with rheumatoid arthritis: an observational study. Drugs in Context, 1. https://doi.org/10.7573/dic.2026-1-2
Vancouver
Kakehasi AM, Sperancini Amaral JGL, Martins Amaral J, Ubirajara E Silva de Souza MPG, de Souza VA, Damian GB, et al. Lack of association between rheumatoid factor levels and clinical response to certolizumab pegol in patients with rheumatoid arthritis: an observational study. Drugs in Context. 2026:1. doi:10.7573/dic.2026-1-2
BibTeX
@article{Kakehasi2026,
author = {Kakehasi, Adriana Maria and Sperancini Amaral, João Gabriel Leão and Martins Amaral, Jéssica and Ubirajara E Silva de Souza, Mariana Peixoto Guimarães and de Souza, Viviane Angelina and Damian, Guilherme Benedini and Torigoe, Dawton Y},
title = {Lack of association between rheumatoid factor levels and clinical response to certolizumab pegol in patients with rheumatoid arthritis: an observational study},
journal = {Drugs in Context},
year = {2026},
pages = {1},
doi = {10.7573/dic.2026-1-2}
}
EUVIMED